Equities Analysts Issue Forecasts for Becton, Dickinson and Company’s Q1 2023 Earnings (NYSE:BDX)

Becton, Dickinson and Company (NYSE:BDXGet Rating) – William Blair issued their Q1 2023 earnings estimates for shares of Becton, Dickinson and in a note issued to investors on Thursday, May 5th. William Blair analyst B. Weinstein forecasts that the medical instruments supplier will earn $3.25 per share for the quarter. William Blair also issued estimates for Becton, Dickinson and’s Q2 2023 earnings at $3.44 EPS, Q4 2023 earnings at $3.84 EPS and FY2023 earnings at $14.15 EPS.

Becton, Dickinson and (NYSE:BDXGet Rating) last posted its earnings results on Thursday, May 5th. The medical instruments supplier reported $3.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.99 by $0.19. The company had revenue of $5.01 billion during the quarter, compared to analyst estimates of $4.78 billion. Becton, Dickinson and had a return on equity of 14.91% and a net margin of 9.59%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company earned $3.19 EPS.

Several other equities research analysts have also recently commented on BDX. Piper Sandler cut their target price on Becton, Dickinson and from $265.00 to $255.00 in a research note on Thursday. SVB Leerink boosted their target price on Becton, Dickinson and from $270.00 to $275.00 and gave the stock a “market perform” rating in a report on Friday, February 4th. Bank of America initiated coverage on Becton, Dickinson and in a report on Tuesday, March 1st. They issued a “neutral” rating on the stock. Argus upped their target price on Becton, Dickinson and from $275.00 to $310.00 in a research report on Monday, February 28th. Finally, Morgan Stanley increased their target price on Becton, Dickinson and from $293.00 to $295.00 and gave the company an “overweight” rating in a research report on Monday, April 11th. Seven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and has a consensus rating of “Hold” and an average target price of $275.63.

NYSE:BDX opened at $257.97 on Monday. The stock has a market capitalization of $73.46 billion, a PE ratio of 40.69, a price-to-earnings-growth ratio of 3.21 and a beta of 0.64. The business’s 50-day simple moving average is $263.40 and its 200-day simple moving average is $257.30. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.53 and a quick ratio of 0.78. Becton, Dickinson and has a fifty-two week low of $235.13 and a fifty-two week high of $280.62.

A number of large investors have recently made changes to their positions in the stock. Accel Wealth Management grew its stake in shares of Becton, Dickinson and by 100.0% in the 4th quarter. Accel Wealth Management now owns 100 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 50 shares during the last quarter. Sierra Capital LLC grew its stake in shares of Becton, Dickinson and by 88.7% in the 4th quarter. Sierra Capital LLC now owns 100 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the last quarter. Level Financial Advisors Inc. bought a new position in Becton, Dickinson and in the 4th quarter valued at approximately $26,000. Icapital Wealth LLC bought a new position in Becton, Dickinson and in the 1st quarter valued at approximately $31,000. Finally, Disciplined Investments LLC bought a new position in Becton, Dickinson and in the 1st quarter valued at approximately $32,000. Institutional investors own 86.58% of the company’s stock.

In other news, Director Claire Fraser sold 841 shares of the business’s stock in a transaction dated Tuesday, February 8th. The stock was sold at an average price of $271.70, for a total value of $228,499.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Betty D. Larson sold 14,374 shares of the business’s stock in a transaction dated Friday, February 25th. The shares were sold at an average price of $271.90, for a total value of $3,908,290.60. The disclosure for this sale can be found here. 0.50% of the stock is owned by insiders.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 30th. Investors of record on Thursday, June 9th will be given a dividend of $0.87 per share. This represents a $3.48 annualized dividend and a yield of 1.35%. Becton, Dickinson and’s payout ratio is 54.89%.

About Becton, Dickinson and (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Articles

Earnings History and Estimates for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.